Respiratory syncytial virus (RSV) is a common respiratory virus which disproportionally affects new-borns and infants.

Vaccination during pregnancy shows about 70% to 80% effectiveness in protecting newborns through antibody transfer. For adults over 60, vaccines demonstrate roughly 75% real-world effectiveness ...

(RTTNews) - GSK plc (GSK, GSK.L) said that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion by consensus recommending approval of ...

Pfizer’s respiratory syncytial virus vaccine was more than 90% effective among older adults during the first season it was available, including among those with underlying conditions or severe disease ...

An experimental vaccine against respiratory syncytial virus (RSV), one of the leading causes of infectious disease deaths in infants, has shown early promise in a Phase 1 human clinical trial. A team ...

A new study has shown that human T cells have an important role to play in controlling infection. Respiratory Syncytial Virus (RSV) is a highly contagious and seasonal respiratory virus that mainly ...

A common respiratory viral infection that causes mild, cold-like symptoms is the respiratory syncytial virus (RSV), also known as the human respiratory syncytial virus (hRSV). However, ections can ...

Health officials reported that cases of human metapneumovirus (HMPV) spiked this spring as COVID-19 and Respiratory Syncytial Virus cases fell. National data from the Centers for Disease Control and ...

Human respiratory syncytial virus (RSV) nonstructural protein 2 (NS2) inhibits host interferon (IFN) responses stimulated by RSV infection by targeting early steps in the IFN-signaling pathway. But ...

The United States may be headed for a rough flu season, with a virus that causes more severe symptoms than the one last year ...